2. Signaling Pathways
  3. HOXA
  4. HOXA Inhibitor

HOXA Inhibitor

HOXA Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-134258
    MEISi-1
    		Inhibitor 98.76%
    MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer.
  • HY-134259
    MEISi-2
    		Inhibitor 98.97%
    MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer.
  • HY-132870
    MEIS-IN-2
    		Inhibitor 99.33%
    MEIS-IN-2 is a myeloid ecotropic viral integration site 1 (MEIS1) inhibitor.
  • HY-132869
    MEIS-IN-1
    		Inhibitor 99.32%
    MEIS-IN-1 is a potent myeloid ecotropic viral integration site (MEIS) inhibitor to induce murine and human hematopoietic stem-cell expansion.
  • HY-178172
    AF9/ENL-DOT1L PPI-IN-1
    		Inhibitor
    AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent AF9/ENL and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC50 = 1.5 μM), AF9-AF4 (IC50 = 1 μM), ENL-AF4 (IC50 = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia[1].
  • HY-132871
    MEIS-IN-3
    		Inhibitor
    MEIS-IN-3 is a potent myeloid ecotropic viral integration site (MEIS) inhibitor.